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A B S T R A C TObjectives: The objective of this study was to assess the potential for
cost-effectiveness of new technologies for chronic obstructive pul-
monary disease (COPD) over the period from 2001 to 2010. Methods:
Lung function outcomes and drug prices were observed for a UK COPD
population over the period from 2001 to 2010. Cost-effectiveness was
assessed at regular intervals on the basis of an established cost-
effectiveness model, and the maximum price a technology providing
cure could achieve under the current cost-effectiveness rules was
estimated. Results: The results of this study show that although the
scope for clinical improvement in COPD was still considerable, during
the 10 years studied, the potential for cost-effectiveness at each point
in time was dependent on momentary market characteristics, such as
the changing price of comparators and improvements in clinicalsee front matter Copyright & 2013, International
r Inc.
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otterdam, The Netherlands.effectiveness. As a result, the analysis demonstrates that the future
cost-effectiveness of a technology in development depends on the
manner pricing and clinical effectiveness evolve throughout time.
Conclusions: Because any predictions will be short-lived and depen-
dent on a number of uncertain factors, we conclude that producing
accurate forecasts on the potential for cost-effectiveness of new
therapies earlier during the development process is especially difficult
under the current static cost-effectiveness framework.
Keywords: chronic obstructive pulmonary disease, cost-effectiveness,
dynamic efficiency, pharmaceutical innovation, pharmaceutical
policy, research and development.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Policy Context
The use of a decision-making framework based on cost-
effectiveness is intended to achieve efficiency in drug spending
by requiring an acceptable and affordable cost per unit of
incremental effect for a new drug compared with existing
therapies. However, with price variation over time due to market
competition, the launch of new drugs, or the entrance of generic
products [1,2], the incremental clinical effectiveness required for
any drug to be cost-effective will change. In addition, the mini-
mum price at which a company can launch a drug will be
affected by a number of factors, such as the level and cost of
regulation, the cost of capital, the size of the target population,
the effective patent time before competitors reach the market, or
the expected speed of market introduction [3–5].
Throughout the drug development process, candidates for new
drugs are traditionally subjected to a rigorous portfolio assessment
exercise. The most viable molecules are selected on the basis of arange of factors such as the probability of regulatory success of the
compound and clinical unmet need of the disease area and
estimated return on investment. Because this process starts many
years before the product enters the market, investment decisions
in drug development are obviously surrounded by considerable
uncertainty. If the expected returns accrued during the approxi-
mately 10 to 12 years of market exclusivity do not cover for the
cost of development, the candidate drug will not be brought into
development and resources will be placed elsewhere.
Contrasting with the dynamic nature of drug development,
coverage and reimbursement decisions are increasingly based on
a static notion of efficiency. In addition, contrarily to what
happens in the drug development process, decisions are made
at a single point in time. This has been suggested to cause a
clash between the objectives of efficiently allocating available
resources and fostering innovation in health care [6,7]. This study
attempts to facilitate the discussion on the importance of cost-
effectiveness in directing research in health care. It assesses how
static cost-effectiveness rules may influence the dynamic envir-
onment of drug development, and examines the implications ofSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
alth Policy and Management, Erasmus University Rotterdam, P.O.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 2 6 – 4 3 3 427taking static cost-effectiveness into account when developing
drugs that will be valued and paid for.
Theoretical Background
This study tests empirically the assumptions underlying the
framework proposed by Refoios Camejo et al. [6]. They suggest
the existence of a physiologically defined clinical effectiveness
ceiling for each disease area (ED max), that is, a medical optimum
from which health would not improve with the use of more
health care. The maximum incremental clinical effectiveness (IEd
max) a new drug could attain over the effectiveness of existing
standard care (Ec) if research and development resources were
infinite is then defined by IEd max ¼ ED max  Ec. Previous
studies [8] have used a similar approach to assess the effect of
price reduction over time on the size of the clinical benefit
necessary for a new drug to be considered cost-effective.
Funding systems based on cost-effectiveness judge a new
technology as cost-effective when the incremental monetary ben-
efit provided is expected to be greater than the incremental costs
incurred by adopting a new technology d over the available
alternative c. This means that a new technology will be approved
to be used in the health system if the net monetary benefit
(NMB) achieved by funding is greater than zero; that is, NMBd ¼
(Ed  Ec)L  (Pd  Pc) 4 0, where L represents a general cost-
effectiveness threshold defining the acceptable cost per unit of
incremental benefit and which is used to monetize health-related
benefits. Because, within the context of a restricted budget, the
adoption of a new technology necessarily implies the withdrawal of
other (less cost-effective) technologies, this threshold is also said to
represent the minimum opportunity cost of funding a new tech-
nology, that is, the benefits forgone by disinvesting in displaced
technologies. The use of a single cost-effectiveness threshold is also
suggested to allow the prioritization across diseases attempting to
signal the areas in which research may be socially preferable.
In the case in which all the benefits of innovation accrue to the
producer and producer surplus is maximized, NMB is set to equal
zero and the price is set so that (Pd  Pc) ¼ (Ed  Ec)L. In this way,
the maximum price premium (PD max) warranting a positive
decision when reaching ED max can be computed at each time
point by taking into consideration the price of the comparator (Pc)
and the clinical effectiveness of standard care (Ec). While Pc will
greatly depend on the market characteristics and the shape of the
innovation curve in that particular disease area, which, in turn, is
dependent on the timing of new products entering the market and
the magnitude of the clinical effectiveness increment they may
bring, IEd max will tend to decrease over time because of incre-
mental innovation. At an extreme and under the investment rules
present in the drug development process, if the minimum possible
launch price for a product to be considered a viable investment with
a positive net present value (Pd min) is expected to be higher than
the maximum price allowed by IEd max, no more investment will be
made in research and development in that particular disease area.
In this context, chronic obstructive pulmonary disease (COPD)
was selected to test the proposed framework empirically because
the maximum clinical effectiveness possible (ED max) for the
technologies can be adequately defined through diagnostic tests
or the nonexistence of exacerbation episodes; the level of clinical
effectiveness of standard care (Ec) is expected to have a direct
relationship with drug usage; and confounding factors eventually
affecting the estimation of Ec are relatively small or can be
controlled for.
The Case of COPD
COPD is a lung-related chronic condition lasting over the course
of a patient’s life that primarily affects people with a history ofsmoking. Patients with COPD initially complain of breathlessness
and may also have cough and increased sputum production,
which tend to worsen over time. COPD is a major cause of
morbidity and mortality worldwide, and current estimates of
COPD prevalence in Europe are between 4% and 10% [9].
Lung function is essential for diagnosis and also an indicator
of disease severity. Lung function impairment is measured
through spirometry to derive values of forced vital capacity
(FVC) and forced expiratory volume in 1 second (FEV1). Primary
diagnosis criterion is a ratio of FEV1 to FVC (FEV1/FVC) smaller
than 0.7 [10]. Lung function is often compared with the FEV1pre-
dicted (FEV1p) for a healthy person of similar age, gender, and
body composition. The ratio between FEV1 and FEV1p, called
forced expiratory volume in 1 second as a percentage of predicted
(FEV1%p), is used to determine COPD severity.
Since the late 1980s, a significant shift in the awareness of
COPD has taken place. Previously, there was the widely held
opinion that little could be done to treat patients with COPD, and
spirometry was performed less frequently. The introduction of
new pharmaceuticals together with other system-wide reforms,
however, have been shown to bring benefits and contributed to
change that view. In the particular case of the United Kingdom,
COPD was included in the Quality & Outcomes Framework (QOF)
incentive program for general practitioners introduced in 2004.
Since then, a consistent move toward the routine collection of
spirometry data in primary care became increasingly visible.
The treatment goal for COPD is now to prevent and control
symptoms and reduce the frequency and severity of exacerba-
tions [10]. Disease management is generally characterized by a
stepwise approach depending on disease severity. More recently,
newer treatments for COPD focus on an improved mode of
action, for example, combining therapies into one inhaler and
reducing the dosage frequency. Despite being a relatively recent
area of research in its own right, the development of treatments
for COPD has benefited from the knowledge acquired while
researching medical technologies for other respiratory condi-
tions. This is significant because innovation in treating respira-
tory diseases has also been achieved through the development of
more efficient delivery systems.
Study Objectives and Scope
The objective of this study was to estimate the potential for cost-
effectiveness of new technologies for COPD over time and assess
how that is influenced by the evolution of clinical effectiveness,
and the pricing pattern of available medical alternatives. The
study illustrates how the real-life clinical effectiveness of existing
standard care in the population being managed for COPD has
changed over time. It subsequently uses the price of pharmaceu-
tical standard care to estimate the maximum cost-effectiveness
possible at different points in time and the higher price that a
new technology providing cure could achieve under current cost-
effectiveness rules when entering the market.
Rather than intending to test the clinical and cost-effectiveness
of any particular technology, this study aimed at providing an
overall medium-/long-term perspective of the evolving potential for
cost-effectiveness in COPD. We then discuss the potential impact of
these readings on the development of further technologies.Methods
Lung function outcomes and prices of available drugs were
observed between 2001 and 2010, and cost-effectiveness was
estimated at yearly time points to reflect the prevailing prices
and gap for clinical improvement. Extensive literature is available
on the efficacy of available drugs in managing COPD within
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from controlled trials because of patient heterogeneity, lack of
patient compliance, variations in clinical management, and
changing demographics or health habits. Hence, to estimate the
real-life clinical effectiveness of existing standard care (Ec),the
analysis used real-life clinical data covering a 10-year observation
period.
Medical records of patients identified as being managed for
COPD were compiled, and spirometry test data and COPD-related
exacerbations information were collected. Population outcomes
were derived and residual unmet clinical need (IEd max) was
computed for each year of the analysis. In addition, prevailing
prices for drugs used to manage COPD were collected from 2001
to 2010 and the average yearly price of existing standard care
was estimated by computing the weighted average of drugs used
to manage COPD in each year. Finally, the potential for cost-
effectiveness of new technologies was estimated by using a cost-
effectiveness model. We present the methods for each of these
analytical steps separately below.
Data Sources
Clinical effectiveness
Data were extracted from the Clinical Practice Research Database
(CPRD). The CPRD is an anonymized database of medical records
of general practitioners in the United Kingdom. Data collection
began in 1987, and the database contains data from more than
600 practices based throughout the United Kingdom, providing
information on 12.5 million patients, of which 5 million are
currently active. The CPRD population is considered to be
representative of the UK population, and data held in the CPRD
include patient, practice, and laboratory information.
In this study, extracted data included spirometry measure-
ments and other variables useful to characterize the population
(gender, age, height, smoking status, prescribing history, and
hospitalization episodes). Exacerbations were identified by the
recording of COPD exacerbation or by any emergency admissions
related to COPD (International Classification of Diseases version10
codes J40-J44 and J47 [11]) through Hospital Episodes Statistics
data. In addition, exacerbations were recognized by the prescrip-
tion of oral steroids or short-term antibiotics with an inclusion
code relating to a lower respiratory tract infection.
Price of existing pharmacotherapy standard care
Pricing and market information was collected from Prescription
Cost Analysis (PCA) data [12]. PCA data are based on prescriptions
in England that are sent to the National Health Service Prescrip-
tion Services for payment and cover all prescriptions dispensed
in the community, therefore, representing the great majority of
pharmaceutical expenditure in the National Health Service. The
data set comprised all generic and nongeneric drugs used in
COPD (i.e., included in the British National Formulary’s para-
graphs 3.1.1.1—Selective Beta(2)-Agonists, 3.1.2—Antimuscarinic
Bronchodilators, 3.1.3—Theophylline, and 3.2—Corticosteroids
(Respiratory) [13]) with reported sales in the UK market between
2001 and 2010. Retail pricing (representing the yearly average cost
of the drug before discounts and excluding any dispensing fees)
was available at the product level. Product-specific market yearly
data (such as quantity of presentations sold, number of mole-
cules available, and number of generic products available) were
also collected from PCA.
Analysis
Clinical effectiveness
The baseline population included all newly diagnosed COPD
patients present in the CPRD database who had been prescribedbronchodilators in the period 2001 to 2010. Patients with a
recorded diagnosis of COPD were included in the study. In
addition, patients older than 35 years who had been hospitalized
with a primary or secondary diagnosis of chronic bronchitis,
emphysema, or chronic airway obstructions were also included.
Patients older than 45 years at their first dispensing for bronch-
odilators were included, provided they had no previous record of
asthma diagnosis or any asthma-related episodes.
The cohort entry date was defined as the date of the first
bronchodilator drug prescription, and patients were required to
have at least 6 months of bronchodilator-free history before
cohort entry date. Patients with spirometry test results showing
a FEV1%p of 80% or more or FEV1/FVC of 70% or more at diagnosis
were excluded. In addition, patients without a recorded test
result within 15 months after cohort entry date were also
excluded. In the case FEV1 or FEV1%p values were not recorded
or FEV1 could not be computed by using existent values of FEV1/
FVC and FVC, the patient was excluded from the analysis.
The clinical effectiveness of existing standard care (Ec) was
represented by FEV1%p. FEV1%p was estimated annually during
the study time period by using patients’ first spirometry test
result available within 15 months after the cohort entry date.
When not directly recorded in the patient files, FEV1%p was
computed by dividing FEV1 by FEV1p, with FEV1p being estimated
by using the predictive equations derived by Starkie [14]:
FEV1ðLÞ in men¼1:8590:029 age ðyearsÞþ0:037 height ðcmÞ
FEV1 ðLÞ in women¼0:2250:029 age ðyearsÞþ0:024 heightðcmÞ
To test for possible variation in patient characteristics over
time, age, height, and gender (condensed in the values of FEV1p)
at the time of cohort entry were compared across years by using
one-way analysis of variance. Patient characteristics were also
compared before and after the introduction of the QOF (i.e., 2004)
by using a standard univariate t test. When data were not
available for any of the demographic variables, multiple imputa-
tions was used to deal with missing data.
The calendar year in which the test had been taken (ranging
from 2001 to 2010) was defined as the index date and used to
estimate the population Ec in the year in question. As per
definition, ED max reflected the point at which all mortality and
morbidity associated with COPD was eliminated. This was
assumed to occur when all patients achieved the treatment goal,
defined in the study by FEV1%p of 80% or more and a 1-year
absence of exacerbations and COPD-related hospitalizations. In
other disease areas, treatment goals have changed over time;
however, this is not the case for COPD because the threshold of
spirometry values required for diagnosis has not changed sig-
nificantly during the study period.
The individual increase needed in FEV1%p for a patient to
reach the recommended treatment target was defined as IEd max,
and estimated by IEd max ¼ ED max  Ec [6]. The residual unmet
need, IEd max, was then calculated as the mean of those values in
each calendar year. As a sensitivity analysis, the median popula-
tion IEd max was also computed for each year. All analyses were
conducted by using STATA 11.
Price of existing pharmacotherapy standard care
Drugs for COPD are normally available in the form of one-dose
solid preparations (pills, capsules, or tablets) and in multidose
containers including aerosols or dry powder to be used in
inhaling devices. To determine the yearly price of standard care,
an indicator consisting of the volume-weighted average price per
item prescribed (P/pack) was used. This indicator was preferred
to price per unit because the PCA’s coding of unit results in a
single pill being equivalent to a multidose inhaler independently
of how many administrations it allows. Volume-weighted P/pack
Table 1 – Studied population characteristics at cohort entry including gender, age, height, and forced
expiratory volume in 1 second predicted for a healthy person of the same age and body composition (FEV1p).
Year n Gender
(% male)
Mean  SD
Age (y) Height (cm) FEV1p (L)
2001 75 60.00 71  9 167  8 2.08  0.54
2002 130 63.85 70  10 168  9 2.15  0.58
2003 262 67.28 71  10 169  9 2.20  0.56
2004 1,039 62.28 72  10 168  9 2.09  0.59
2005 1,070 63.36 72  10 168  10 2.11  0.61
2006 1,278 63.93 72  11 169  10 2.14  0.62
2007 1,753 63.30 72  11 169  10 2.13  0.60
2008 2,038 61.86 72  11 168  9 2.12  0.59
2009 2,770 62.58 70  11 169  9 2.17 0.60
2010 6,879 64.54 70  10 169  9 2.22  0.59
Total 17,294 63.54 71  10 169  10 2.17  0.58
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presentations available in each 1-year time period. Volume-
weighted average P/pack was then computed for each subclass
and for the whole therapeutic area (Pc). P/pack was back and
forward dated by using the non–health-specific consumer price
index to account for inflation [15].
Potential for cost-effectiveness
The potential for cost-effectiveness was analyzed by testing the
maximum price a new drug could achieve under the current cost-
effectiveness rules. Using the cost-utility economic model devel-
oped by Starkie [14], the lifetime health-related quality-of-life
benefits and cost savings associated with achieving ED max were
estimated. The model followed a conceptual regression-based
framework and allowed interdependence to exist between the
different components of COPD. Thus, an increase in FEV1%p was
converted into lung function improvement and reflected in
symptoms, exacerbations, survival, health care costs, and utility.
The model followed the base case advocated by the National
Institute for Health and Clinical Excellence in its guide to the
methods of technology appraisal [16].
The cost-utility model was used to predict quality-adjusted
life-year (QALY) and costs associated with existing standard care
by using the yearly population FEV1%p and the weighted-average
P/pack. The potential QALY gained for a treatment achieving ED
max was estimated for each year; and the maximum price
achievable by IEd max (PD max) in light of the National Institute
for Health and Clinical Excellence’s £20,000 per QALY cost-
effectiveness threshold was computed. The demographic char-
acteristics (age and height) of the modeled cohort were defined
on the basis of the average of the values observed across years. To
accommodate potential severity imbalances across gender and
age, all analyses were completed separately by using values for
female and male patients and the overall population results were
adjusted according to their proportion in each year. All calcula-
tions used in estimating cost-effectiveness were conducted by
using prices and costs adjusted to 2006 prices by using the
non–health-specific consumer price index [15].Results
Clinical Effectiveness
Population characteristics
Out of the 210,700 patients identified as COPD patients from 2001
to 2010, 46,426 patients had linked spirometry data. Of these,17,294 patients met the inclusion criteria of having a test result
within 15 months after the cohort entry date and were included
in the analysis. Population characteristics at cohort entry can be
seen in Table 1.
Table 1 shows that the number of people with spirometry
measures has rapidly increased over time, particularly after 2004.
However, this trend did not cause much disparity in terms of
demographic baseline characteristics: the hypothesis that the
mean of FEV1p values (used as a composite measure of gender,
age, and height at baseline) varied across the years was rejected (P
¼ 0.461). In addition, the hypothesis that mean FEV1p values
before and after the introduction of the QOF (i.e., before and after
2004) were different was also rejected and deemed highly insig-
nificant (P ¼ 0.853). In exploratory analyses by gender, mean FEV1p
values across years for female patients (mean ¼ 1.59  0.35) were
found to be significantly lower (P ¼ 0.000) than the mean FEV1p
values for the male population (mean ¼ 2.51  0.41).
FEV1p as a percentage of predicted
Mean population FEV1%p measured within 15 months of cohort
entry was shown to increase fairly steadily, starting close to 51%
in 2001 and increasing to approximately 59% in 2010 (Fig. 1). One-
way analysis of variance confirmed that the difference across the
yearly mean FEV1%p values was statistically significant (P ¼
0.000).
The observed trend of steadily increasing FEV1%p, as shown in
Figure 1, was maintained throughout the study period while IEd
max decreased throughout the study period; however, FEV1%p
values were still some way from the clinical target of 80%, which
means that there was still substantial potential for innovation in
this disease area.
Price of Existing Pharmacotherapy Standard Care
During 2001 to 2010, the market for COPD drugs saw the entrance
of several new therapies and the loss of exclusivity for older
molecules. In total, 14 molecules, in several combinations and
pharmaceutical forms, were available at some point during the
period studied. Because the effectiveness of treatment tends to
be linked with the emergence of new molecules, as well as with
innovative delivery systems, the weighted average P/pack natu-
rally followed the paced introduction of these innovations (Fig. 2)
and generally increased over the study period.
The weighted average nominal P/pack varied throughout the
decade analyzed, fluctuating noticeably and rising 44% overall
from £13.46 per pack in 2001 to £19.61 per pack in 2010 in 2006
pound sterling. The corticosteroid subclass, which included the
Fig. 1 – Mean forced expiratory volume in 1 second as
a percentage of predicted (FEV1%p) in patients being
managed for COPD across the study period. Cure is
assumed to be achieved at the 80% level of FEV1%p
and is represented by the reference line. Yearly IEd
max is represented by the gap between the top of
each bar (showing the yearly mean value of FEV1%p)
and the mentioned reference line. COPD, chronic
obstructive pulmonary disease.
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molecules in new delivery systems, commanded the highest
prices. Real prices in this subclass (as in the selective beta(2)-
agonists subclass), however, showed a significant decreasing
trend. The most striking observation was related to the introduc-
tion of a new molecule (i.e., tiotropium in 2002 in the antimus-
carinic bronchodilators subclass) and its gradual uptake, which
caused a noticeable increase in the average P/pack. Apart from
the case of salmeterol in 2007 in the selective beta(2)-agonists
subclass, loss of exclusivity for older molecules did not appear to
particularly affect average class P/pack.Fig. 2 – Real (in 2006 sterling pound) weighted-
average price per pack (P/pack) for drugs used in COPD
between 2001 and 2010 by therapeutic subclass and
averaged across subclasses—Class P/pack (Pc). COPD,
chronic obstructive pulmonary disease.Potential for Cost-Effectiveness
In the period between 2001 and 2010, the economic model
predicted that 0.28 QALYs were gained per patient because of
the improvement in the management of COPD. This meant that
the absolute potential for incremental clinical effectiveness
measured in terms of health-related quality of life decreased
approximately 25% from 1.09 QALY to 0.81 QALY (Table 2).
Consequently, the maximum possible price for a technology
that increased FEV1%p to 80% and consequently eliminated any
mortality and morbidity associated with COPD was found to
decrease by 12.75% between 2001 and 2010 (Table 2). Never-
theless, the price of a treatment that cured COPD was still
considerably higher than the average price of existing standard
care, which suggests that there is still scope to invest in the
development of new treatments for COPD.
The potential for cost-effectiveness estimated through the
model depended noticeably on the level of effectiveness of
standard care and the prices of comparators. While the former
presented a somewhat linear decreasing trend, the latter was
shown to be susceptible to greater variations. As a consequence,
PD max did not follow a well-defined pattern and the magnitude
of the potential for cost-effectiveness was shown to be momen-
tary and dependent mostly on the transient market
characteristics.
Sensitivity analysis around the modeled cohort, using alter-
native estimates for age and height, did not affect the main
results. When Pc was reduced by 75% (to levels that have been
assumed to be those of a competitive market price where only
generic products were available), PD max in 2010 decreased from
£51.13 to £38.47. This means that the maximum possible price for
a ‘‘curative’’ technology decreased from 2.31 to 1.76 times Pc.Discussion
This study showed that the clinical effectiveness of standard
(pharmaceutical and nonpharmaceutical) disease management
has improved over time, with average FEV1%p increasing from
51% in 2001 to approximately 59% in 2010. This represented a
gain of 0.28 QALYs, which was approximately 25% of the total
clinical benefit possible to achieve. The results show that the
average price of drugs used in COPD varied considerably across
the 10 years studied, and increased nearly 44% overall, reflecting
the introduction of new chemical entities and of new delivery
systems. As expected, all these factors played a role in determin-
ing the potential for cost-effectiveness possible for new drugs
entering the market at different points in time. As a result, the
maximum price achievable under current cost-effectiveness
rules for a drug providing cure decreased by approximately
13%. Although a decreasing trend was noted overall, however,
the predicted potential for cost-effectiveness fluctuated from
year to year because of market variations during the period
studied.
The 10-year observation period of real-life data provided a
comprehensive description of the evolution of disease manage-
ment and the pricing patterns of available treatments. As with
any empirical study relying on observational data, however, the
results from these analyses should be interpreted with caution
because other unobserved factors may be associated with our
findings. The fact that spirometry test results had to be available
for a patient to be included in the study may have led to the
inclusion of more severe patients into the study, because more
severe patients are more likely to have more measurements
recorded.
Also, taking into consideration that these tend to be lifetime
prescriptions with a fairly low compliance, a single observation
Table 2 – Values of maximum incremental clinical effectiveness possible (IEd max) and price of existing
standard care (Pc) used as inputs in the base-case analysis; incremental QALY, and costs associated with a new
treatment achieving IEd max; and the maximum price possible for a drug achieving cure (PD max) in line with
an ICER of £20,000 per QALY.
Year Mean IEd max (FEV1%p in %) Pc (P/pack) (2006 £s) Incremental QALY PD max (P/pack) (2006 £s)
2001 28.85 13.64 1.09 58.74
2002 26.52 15.00 0.99 55.46
2003 25.95 16.98 0.97 56.24
2004 25.30 18.78 0.96 57.20
2005 25.58 20.05 0.96 58.52
2006 23.85 20.40 0.90 56.07
2007 23.34 20.38 0.89 55.45
2008 23.30 19.99 0.88 55.17
2009 21.52 20.17 0.82 52.36
2010 21.27 19.61 0.81 51.25
Note: Costs in the model included drug acquisition costs and other costs incurred in managing the disease, for example, costs of COPD-related
clinical events such as exacerbations.
COPD, chronic obstructive pulmonary disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 2 6 – 4 3 3 431point may have influenced the estimation of Ec. Longer follow-up
and delayed measurement (e.g., use of FEV1 test results 2 years
after cohort entry date), however, would have exceedingly
reduced the sample. Management and awareness of COPD has
changed considerably over the last 20 years and the number of
patients followed up in the study increased throughout the years.
This may have resulted in a relative increase in earlier diagnosis
of potentially less severe patients in the latter years of the study.
Nevertheless, no statistically significant difference was found
between the baselines characteristics of patients included across
the years and before and after 2004, the year the QOF was
introduced.
In addition to a better understanding of the pathophysiology
of the disease and better disease management strategies, the
launch of new medical technologies in the last 10 years has
steadily improved the standard of treatment available. Given the
scope for incremental clinical effectiveness, however, it seems
apparent that disease management in COPD, although improving
over time, is not as advanced as in other areas. Investment in this
particular disease is relatively recent, and it can be argued that
these are early steps and that the innovation curve is still at its
infancy. This scenario is, however, expected to change soon
because several new products are anticipated to enter the market
in the near future taking the management of COPD a step further.
Overall, price variations of standard care comparators were
not linear over time. This resulted both from the introduction of
new technologies and from the constant modification of the
standard treatment mix because of the progressive uptake of
newer technologies. It is also apparent that the generic market is
not truly developed in COPD and that the extent of potential price
decreases due to generic entry was smaller than normally
experienced in other disease areas. This was probably because
some of the highly used drugs and inhalers are still under patent
protection. When loss of exclusivity occurred, older molecules
appeared to be replaced by newer technologies and the average
price of available technologies was not significantly affected. In
addition, the dual-innovation system based both on chemical
entities and on drug delivery devices may create an intellectual
property picture that is more intricate than that of a normal
market.
In this analysis, the standard level of care was estimated by
measuring the effectiveness in the whole disease spectrum.
However, cost-effectiveness of a new technology is normally
judged on the basis of clinical trials efficacy. How that efficacytranslates in practice into effectiveness is dependent on the
efficiency of the health system itself, which the developer cannot
control. In this study, it was assumed that a new technology
would deliver its full potential to provide cure, which presumes
that the system would also be optimized. Particular interventions
or tools such as improved diagnostic tests can sometimes work
as catalysts for the necessary system innovation. Hence, there is
a rationale for individual cost-effectiveness to be considered
under a more holistic approach recognizing the importance of
the health care delivery chain in working toward the optimal
technology introduction and usage.
As expected, the potential for cost-effectiveness suffered a
reduction overall in the 10 years studied. The study, however,
shows that it remained high during the period studied, and the
fact that the maximum price obtainable for a treatment that
eventually cured COPD was considerably higher than the average
cost of available drugs suggests that the incentive to invest in
COPD was present throughout. This is mostly due to the increase
observed in the price of comparators, which prevented a further
erosion of PD max. However, whilst this happened for COPD with
its particular market structure, this has be found not to be the
case in other disease areas where price erosion occurred and
considerably diminished the potential for cost effectiveness [8].
Hence, as postulated by Refoios Camejo et al. [6], these results,
in conjunction with previous studies, illustrate that the factors
influencing the prediction of cost-effectiveness of new technol-
ogies are highly dependent on the rate of incremental clinical
advancements and the pricing patterns in each particular
disease area.
Because of the nature of drug research and the regulatory
processes in place, the conditions of the market need to be
predicted at early stages of development 10 or more years before
they occur. This is naturally difficult and challenges the alloca-
tion of research and development funding. Early cost-
effectiveness prediction is suggested to be able to play a role in
reducing investment uncertainty by signaling the payers’ will-
ingness to pay for a particular health benefit. The prediction of a
technology’s future cost-effectiveness, however, is not straight-
forward because the evolution of the market depends not only on
the future performance of the technology being developed but
also on the success of competitor technologies in development
elsewhere at the same time.
The results from this study corroborate this idea and suggest
that the variation in the pricing patterns does not necessarily
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Prices of available technologies will depend on the particular
characteristics of the pharmaceutical market, such as the num-
ber of competitors or the degree and pace of generic introduction.
In addition, clinical effectiveness within a disease area evolves
with many factors such as the introduction of new technologies,
the development of new means of diagnostic, or the wider
adherence to clinical guidelines. When cost-effectiveness poten-
tial is momentary and dependent on the transient conditions of
the market, a positive decision on whether to fund a technology
based on cost-effectiveness may end up being highly dependent
on the particular timing of the appraisal. This dynamic nature is
present throughout the product’s lifecycle and, being different
across diseases, will be difficult to capture at a single point of
market entry when price is decided upon by using a general cost-
effectiveness threshold.
This introduces uncertainty into the development process and
consequently results in higher costs of development. In practice,
it may produce an inefficient allocation of research and develop-
ment resources; that is, either overinvestment will take place or
affordable research will be foregone with investment being short
of the societal optimal. Ultimately, considering that pharmaceu-
tical innovation is path dependent, this increased uncertainty
surrounding the cost-effectiveness potential may result in the
complete withdrawal from research within a particular disease
area. In addition, because different disease areas are constantly
competing for research and development funds, any influence
cost-effectiveness might have in directing drug development to a
particular health condition may be distorted.
Cost-effectiveness still has an essential role to play in signal-
ing the health systems’ willingness to pay and in directing
research to the areas society values most.
However, this can be achieved only if the current decision-
making framework is adapted to incorporate the dynamic nature
of drug development and the specificities of the disease area.
Although some reimbursement bodies may already consider some
of these concerns in the appraisal stage of the decision-making
process by allowing higher thresholds when certain requirements
are met [16–18], a more structured approach may be necessary.
Suggestions on how to tackle this issue explicitly may, for instance,
entail the designation of silo disease-specific budgets based on the
societal preferences for treating particular diseases, and disease-
specific thresholds defined to represent the shadow price of such
budgets. Alternatively, two budgetary components could be defined
separately: the first would be dependent on the total health care
budget with a threshold defined on the basis of the foregone
benefit of displacing other technologies elsewhere in the health
system and the second component would imply the definition of a
global innovation budget, subdefined by disease area. In any case,
further research and a wider debate will be necessary to devise a
system that allows cost-effectiveness to efficiently direct invest-
ment in pharmaceutical research.Conclusions
The results of this study show that despite the noticeable advance-
ment in managing COPD in recent years, clinical unmet need is
substantial and there is significant scope for clinical improvement
in this disease area. The potential for future cost-effectiveness, as
judged by current cost-effectiveness rules, decreased but it is still
considerable. This was found to be the case because innovation in
COPD is still at its infancy and, contrarily to what was seen in other
disease areas, the impact of generic entry had not had a marked
effect on the price of existing comparators. The analysis further
suggests that during the 10 years studied, the potential for cost-
effectiveness of new therapies was momentary, dependent on thetransient market characteristics and specific to each disease area,
and so any predictions of future cost-effectiveness are naturally
short-lived. As a result, under the current static cost-effectiveness
framework, it is especially difficult to produce accurate estimates
of the potential for cost-effectiveness of new therapies earlier in
the development process.Acknowledgments
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